Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.

@article{Humerickhouse1999PhaseIS,
  title={Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.},
  author={Rod A. Humerickhouse and M. Eileen Dolan and Daniel J. Haraf and B Brockstein and Kristina Stenson and M Kies and L Sulzen and Mark J. Ratain and Everett E. Vokes},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={1999},
  volume={5 2},
  pages={291-8}
}
5-Fluorouracil (5-FU) is an effective enhancer of radiation therapy (RT) in head and neck cancers. Due to rapid, predominantly hepatic metabolism by dihydropyrimidine dehydrogenase (DPD) and suggested clinical benefit from prolonged drug exposure, 5-FU is commonly given by continuous infusion. Eniluracil is a novel DPD-inactivator designed to prolong the half-life of 5-FU and provide sustained plasma concentrations of 5-FU with oral dosing. We conducted a Phase I study of the safety and… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

No evidence of gemcitabine accumulation during weekly administration

European Journal of Clinical Pharmacology • 2005
View 1 Excerpt

Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibition.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2002
View 3 Excerpts

Pharmacology of Fluorinated Pyrimidines: Eniluracil

Investigational New Drugs • 2000
View 1 Excerpt

The oral fluoropyrimidines in cancer chemotherapy.

Clinical cancer research : an official journal of the American Association for Cancer Research • 1999

References

Publications referenced by this paper.
Showing 1-10 of 21 references

A Phase II study of a five day regimen of oral 5-fluorouracil (5-FU) plus GW776 (776C85) with or without leucovorin in patients with metastatic colorectal cancer

R. Schilsky, R. Bokowski, +7 authors J. Hohneker
Proc. Am. Soc. Clin. Oncol., • 1997
View 1 Excerpt

Intense combined therapy with C-DDP, 5-FU, hydroxyurea, and BID radiotherapy (C-FHX) for stage IV squamous cell cancer (SCC) of the head and neck

M. S. Kies, D. J. Haraf, +8 authors E. E. Vokes
Proc. Am. Soc. Clin. Oncol., • 1996

Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 1995
View 1 Excerpt

A Phase II trial of induction cisplatin, 5FU, leucovorin and interferon a-2B (PFL-a) followed by concurrent hydrea-5FU and radiation for stage IV squamous cell cancers of the head and neck (HNC)

M. S. Kies, D. J. Haraf, +11 authors E. E. Vokes
Cancer Treatment: An Update, • 1994

Similar Papers

Loading similar papers…